CeriBell (NASDAQ:CBLL) Sets New 52-Week High – Still a Buy?

CeriBell, Inc. (NASDAQ:CBLL)’s share price hit a new 52-week high on Monday . The stock traded as high as $24.44 and last traded at $24.40, with a volume of 396312 shares trading hands. The stock had previously closed at $23.33.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CBLL. BTIG Research reissued a “buy” rating and issued a $28.00 price target on shares of CeriBell in a research report on Tuesday, August 11th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, Canaccord Genuity Group raised their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.00.

CeriBell Trading Up 4.6%

The company’s fifty day moving average price is $18.93 and its two-hundred day moving average price is $19.09. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The company has a market cap of $936.42 million, a price-to-earnings ratio of -13.86 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Insider Buying and Selling at CeriBell

In other news, Director William W. Burke sold 2,207 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the sale, the director directly owned 23,022 shares of the company’s stock, valued at $456,756.48. This represents a 8.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph Michael Taylor sold 13,095 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the transaction, the director owned 48,478 shares of the company’s stock, valued at $1,134,385.20. This trade represents a 21.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 313,780 shares of company stock worth $6,241,749 over the last quarter. Corporate insiders own 17.70% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio acquired a new position in CeriBell during the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd raised its stake in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the third quarter valued at approximately $33,000. CWM LLC lifted its holdings in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.